Hansa Biopharma AB (HNSA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Swedencare AB

Swedish Orphan Biovitrum AB

Camurus AB

Calliditas Therapeutics AB

BioArctic AB

Egetis Therapeutics AB

Vicore Pharma Holding AB

Hansa Biopharma AB

Xspray Pharma AB

Infant Bacterial Therapeutics AB

FluoGuide A/S

Why is Hansa Biopharma AB ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -5.08% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -118.62

The company has declared negative results for the last 2 consecutive quarters

INTEREST(HY) At SEK 114.39 MM has Grown at 156.5%
NET SALES(HY) At SEK 82.67 MM has Grown at -28.41%
PRE-TAX PROFIT(Q) Lowest at SEK -229.33 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 33.95%, its profits have fallen by -1.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

No Data Found

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

105.26%

EBIT Growth (5y)

-5.08%

EBIT to Interest (avg)

-32.49

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.22

Sales to Capital Employed (avg)

0.32

Tax Ratio

0.35%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-10.66

EV to EBIT

-5.96

EV to EBITDA

-5.96

EV to Capital Employed

18.08

EV to Sales

17.84

PEG Ratio

Dividend Yield

ROCE (Latest)

-303.40%

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

NET PROFIT(HY)

Higher at SEK -426.33 MM

-26What is not working for the Company

INTEREST(HY)

At SEK 114.39 MM has Grown at 156.5%

NET SALES(HY)

At SEK 82.67 MM has Grown at -28.41%

PRE-TAX PROFIT(Q)

Lowest at SEK -229.33 MM

RAW MATERIAL COST(Y)

Grown by 15.66% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -92.46 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.08 times

NET PROFIT(Q)

Lowest at SEK -230.01 MM

EPS(Q)

Lowest at SEK -2.61

Here's what is working for Hansa Biopharma AB

Depreciation

Highest at SEK 11.67 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (SEK MM)

Depreciation

At SEK 11.67 MM has Grown at inf%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (SEK MM)

Here's what is not working for Hansa Biopharma AB

Pre-Tax Profit

At SEK -229.33 MM has Fallen at -46.38%

over average net sales of the previous four periods of SEK -156.67 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (SEK MM)

Net Profit

At SEK -230.01 MM has Fallen at -46.26%

over average net sales of the previous four periods of SEK -157.26 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (SEK MM)

Interest

At SEK 114.39 MM has Grown at 156.5%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Pre-Tax Profit

Lowest at SEK -229.33 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (SEK MM)

Net Sales

At SEK 82.67 MM has Grown at -28.41%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (SEK MM)

Net Profit

Lowest at SEK -230.01 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (SEK MM)

EPS

Lowest at SEK -2.61

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (SEK)

Debt-Equity Ratio

Highest at -92.46 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 1.08 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 15.66% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales